TRBC1 and angioimmunoblastic T-cell lymphoma: A phase I/II study at the recruiting phase will evaluate AUTO4 (anti-TRBC1 CAR-T cells) in AITL patients with TRBC1 CD4+ malignant cell clonality (NCT03590574 and NCT0482817).